摘要
目的:系统评价心可舒干预冠心病合并焦虑、抑郁的有效性及安全性。方法:使用计算机检索中国知网数据库(CNKI)、万方数据库(WanFang Data)、中国生物医学文献数据库(CBM)、维普(VIP)、PubMed、the Cochrane Library数据库,检索时限均从建库至2022年7月29日,全面搜集心可舒干预冠心病合并焦虑、抑郁的随机对照试验,根据纳入及排除标准进行文献筛选与资料提取,对纳入的研究进行质量评价,采用Review Manager 5.3软件进行Meta分析。结果:共纳入研究18项,涉及1730例病人,其中试验组877例,对照组853例,Jadad评分的平均分为3.44分。Meta分析结果显示,试验组在冠心病临床症状及心电图改善率[RR=1.31,95%CI(1.18,1.45),P<0.00001]、焦虑抑郁缓解有效率[RR=1.55,95%CI(1.26,1.90),P<0.0001]、抑郁评分量表减分率[SMD=1.33,95%CI(0.88,1.78),P<0.00001]、焦虑量表评分减分率[SMD=1.87,95%CI(1.25,2.48),P<0.00001]、LDL-C改善程度[MD=0.09,95%CI(0.03,0.16),P=0.003]、TC改善程度[MD=0.72,95%CI(0.08,1.37),P=0.03]、TG改善程度[MD=0.18,95%CI(0.11,0.25),P<0.00001]方面优于对照组,差异均有统计学意义。两组不良反应发生率比较差异无统计学意义[RR=1.00,95%CI(0.34,2.97),P=1.00]。结论:现有研究表明,心可舒联合冠心病基础治疗可进一步改善冠心病合并焦虑抑郁病人的临床症状、心电图表现,缓解焦虑、抑郁情绪,调节血脂,安全性良好。
Objective:To evaluate the efficacy and safety of Xinkeshu in treating coronary heart disease with anxiety depression.Methods:The databases of CNKI,WanFang Data,CBM,VIP,PubMed,and the Cochrane Library were searched by computer from the establishment of the database to July 29,2022.Randomized controlled trials of Xinkeshu treating coronary heart disease with anxiety depression were comprehensively collected.Literature selection and data extraction were conducted according to the inclusion criteria,and the quality of the included studies was evaluated.Meta-analysis was performed using Review Manager 5.3 software.Results:A total of 18 studies were included,including 1730 patients,among which 877 in experimental group and 853 in control group.The average Jadad score was 3.44.The results of meta-analysis showed that in experimental group,the clinical symptoms and electrocardiogram(ECG)improvement rate[RR=1.31,95%CI(1.18,1.45),P<0.00001],the relief rate of anxiety and depression[RR=1.55,95%CI(1.26,1.90),P<0.0001],Depression Scale Score reduction rate[SMD=1.33,95%CI(0.88,1.78),P<0.00001],Anxiety Scale Score reduction rate[SMD=1.87,95%CI(1.25,2.48),P<0.00001],low-density lipoprotein cholesterol(LDL-C)improvement rate[MD=0.09,95%CI(0.03,0.16),P=0.003],total cholesterol(TC)improvement rate[MD=0.72,95%CI(0.08,1.37),P=0.03],triglyceride(TG)improvement rate[MD=0.18,95%CI(0.11,0.25),P<0.00001]were better than those in control group,and the differences were statistically significant.There was no significant difference in the incidence of adverse reactions between two groups[RR=1.00,95%CI(0.34,2.97),P=1.00].Conclusion:Existing studies show that Xinkeshu combined with basic treatment of coronary heart disease can further improve the clinical symptoms and ECG performance,relieve anxiety and depression,regulate blood lipid of patients with coronary heart disease with anxiety depression safely.
作者
吴亦荷
来晓磊
刘红旭
连妍洁
WU Yihe;LAI Xiaolei;LIU Hongxu;LIAN Yanjie(Beijing Hospital of Traditional Chinese Medicine,Capital Medical University,Beijing 100010,China;Beijing University of Traditional Chinese Medicine,Beijing 100029,China)
出处
《中西医结合心脑血管病杂志》
2023年第1期21-31,共11页
Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
基金
国家中医药管理局中医药循证能力建设项目-专科专病循证能力提升(No.2019XZZX-XXG001)。
关键词
冠心病
焦虑
抑郁
心可舒
系统评价
coronary heart disease
anxiety
depression
Xinkeshu
systematic review
